Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Tremendous endorsement of our product. A company with £27 billion market cap sees quality and value in this little tiddler. Under the radar currently but if this contract goes well then a further roll out with Compass Group a distinct possibilty. Long term contracts with extremely high margins.
Morning everyone. It's a fairly routine Feedback RNS, designed to tease and tempt with lots of speculation. Was a shareholder for 7 years, met all the board and decided to withdraw. Last 20 years Cadran contracts have been for 2 year period, it's now 14 months. As usual absolutely no indication of revenues, Bleepa will be free i assume initially, but most importantly for me they have never once got anything over the line, a Hans Christian Andersen company. Good luck to those invested, hope I'm wrong but suspect not.
Trevor is a shrewd operator, not everyone's cup of tea but a guy I follow closely. He has invested huge sums of his own in this company and you can be sure he's confident of the company future. He is also always rigidly on top of costs and overheads which is one of the reasons he parted from Feedback where I was a long term holder. In terms of the fundraise its quite possible it was tentatively broached before the spike and compared with SP of a few days ago, it's actually at a premium.
It's AIM, where we know games are played and investors too, but I have no doubt the likes of Riddler and Smudgedan have researched effectively and can expect a decent return. These small caps took a major hit at the beginning of Coronavirus and some are looking extremely cheap in market cap. terms. This is one of those and although I wasn't in the placing I invested at significantly below that level. I think Trevor will provide good news in due course. Another of his companies BRH is also expected to benefit from the current demand of equipment and consumables to meet Coronavirus needs. I am invested in both.
Interim results 18 February, 'further investment in Texrad put on hold'. Don't expect anything to materialize 're Texrad.TO spent weeks/months not responding to shareholders contacts now PR appearing. Only 1 reason, fundraise within 3 months imho.
People playing down sales figure, need to remember it's only 3 weeks worth! Extrapolate and include OEM USA deal. It's very impressive!
Morning CC. I held nearly 2% with family and friends for nearly 7 years but no longer hold. The company have been disingenuous for years and even a mildly forensic examination of RNS and interviews during that period presents so many red flags I'm surprised FCA haven't had a look. They've raised £5.375m over 3 years, overheads have quadrupled and sales are stagnant. They will require further funding within 6 months with further massive dilution to shareholders and still, after 7 years have not brought a commercial revenue earning product to market. I was given categoric assurance that Texrad Lung would be brought to market for NHS England CT scans, they even RNS to this effect. Latest interview with CEO, he states that there is insufficient evidence to commercialize Texrad! Overheads continue to increase at pace, recently announced deals will yield little sales revenue in my opinion. Met with board last year and told them financial business model unsustainable, Riddell smiles and says 'we're confident'. Emperor's clothes gentlemen. Good luck with investment.
He's another overhead draft. Company has poor history with comms and delivery, market will react positively when it believes.....
Jacksdad, it's not so strange. There have been many, and I mean many, false dawns over the years. They have been awful at communicating real progress because little progress exists. I am a long term holder , 6 years, the financial statements and repeated dilution tell you all you need to know. The markets will only believe if there is irrefutable evidence that things have changed. Even at this price the board aren't clambering to buy stock....
Hi Botak, Elartu is correct I think. Bleeps is linked to hospital PACS system and clinical quality images to enable clinicians decision making. Forward requires a photograph and is not linked. Bleepa USP is image quality and certainty of accurate decisions.
Summary of affairs accurately posted again Mr Brown, please don't hang around. Some of us long termers don't need more depressing. While you're about did you use Texrad as part of FDA submission for IQAI? Are you planning on buying Texrad? Would fit really well in your portfolio. Go on, make Tom an offer.
Interesting RNS, why did outgoing Chairman allow Prince Andrew and Lady Colin Campbell to write his exit statement?
Hi draft, I am a long term holder, 7 years to be precise. Am in a tightly knit group of family and friends and many attempts to communicate by those within the group have fallen on deaf ears. We are not lying, they don't like answering difficult questions and comms over the years have been awful and at times blatantly dishonest. ie. 'Texrad lung will be used in clinical settings before the end of 2018'. If you read the last 3years RNS they have been consistent in one area, they have failed to deliver. However they have still managed to raise £5.375 million in placing during that period, mostly thanks in no small measure to Tom Charlton and Jonathan Cranston. I had meeting with the board earlier in the year and they were supremely confident. CEO has not bought any stock to support the efforts of Jonathan and Tom, massive dilution over the period. Still hold but it's always been about Texrad for me and its potentially successful intervention tackling cancer in early stages. Very little reported on any progress in this area for a long time in spite of Riddell positivity in the period. Good luck with investment.
You're not alone cc, I know of at least 3 long term holders who haven't had 'replies.
Perhaps it's because our intelligent, well reasoned questions are too challenging. They always exchange emails when things are positive!
All is not lost. New board and senior management, Buckingham will be gone in due course and new direction will emerge, AIMO.
Read finals 'cash resources until October 2020'.
Morning Elartu and Botak. Clearly a great opportunity for company, if they've done proper due diligence and with major concerns about information security bleepa should be welcomed by all. Can they get it over the line? It'll be the first.
Great question, I'll be asking the company the same.
Reflects Paul Ryan Director purchase in the recent fundraising. Confident enough to support with £50,000.
Always backs his own companies, has done so again here. This will be successful given time, recent interview with recently acquired Cloudveil talked of transformational products in systems security plus Gyrometric in a growing space with industry best product suite for engineering monitoring. This will do very well in my opinion.
Morning fellow shareholder! Have been invested here for 6 years and it requires lots of patience I can tell you. Previous placing have been specifically to seek FDA approval for Texrad range of products although no recent news on progress. I can only assume bleepa product development and due diligence has taken all energies. It's a very small company with great products and low resources has always meant progress slow.
I met with board and staff in February and as impressed with clinical background , contacts and knowledge. Professor Rory Shaw, incoming Chairman will be a huge asset imho. I have no knowledge 're litigious claims for use of whatsapp but given how these 'no win no fee' lawyers operate it's only a matter of time before floodgates open. It's incumbent on clinicians and NHS to guarantee information security and bleepa appears to offer this. Sorry I can't be more helpful.